Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 366 | 37 | 329 |
| Samples | 179 | 17 | 162 |
| Peptides | 159 | 19 | 140 |
Function
SARS · Serine--tRNA ligase, cytoplasmic
Catalyzes the attachment of serine to tRNA(Ser) in a two-step reaction: serine is first activated by ATP to form Ser-AMP and then transferred to the acceptor end of tRNA(Ser) (PubMed:22353712, PubMed:24095058, PubMed:26433229, PubMed:28236339, PubMed:34570399, PubMed:36041817, PubMed:9431993). Is probably also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec) (PubMed:26433229, PubMed:28236339, PubMed:34570399, PubMed:9431993). In the nucleus, binds to the VEGFA core promoter and prevents MYC binding and transcriptional activation by MYC (PubMed:24940000). Recruits SIRT2 to the VEGFA promoter, promoting deacetylation of histone H4 at 'Lys-16' (H4K16). Thereby, inhibits the production of VEGFA and sprouting angiogenesis mediated by VEGFA (PubMed:19423847, PubMed:19423848, PubMed:24940000)
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 154 amino-acid changes on canonical ENST00000234677 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SARS · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SARS – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 10/612 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Neuroendocrine Tumour | 1/154 1% | 5/577 1% |
| Bladder Carcinoma | 1/58 2% | 7/956 1% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 13/1390 1% |
| Colorectal Carcinoma | 2/143 1% | 22/3239 1% |
| Gastric Carcinoma | 0/74 0% | 13/1809 1% |
| Melanoma | 0/210 0% | 11/1899 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Hepatocellular Carcinoma | 1/46 2% | 9/2210 0% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Head and Neck Carcinoma | 2/85 2% | 5/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Ovarian Carcinoma | 0/109 0% | 4/998 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Wilms Tumour | 0/5 0% | 1/474 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Kidney Carcinoma | 1/85 1% | 3/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 4/2534 0% |
| Prostate Carcinoma | 1/13 8% | 3/2105 0% |
| Other Blood Cancers | 0/61 0% | 5/2725 0% |
Mutation Distribution
Where SARS is mutated · all tissues, split by cell line vs tissue
How many mutations in SARS were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 366 mutations in SARS
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|